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Summary Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter
received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients
was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.
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Cisplatin and methotrexate are generally regarded as the most
active single agents in the treatment of transitional cell carcinoma
(TCC) of the bladder (Scher and Norton, 1992) and form the
cornerstone of most commonly used chemotherapy combinations.
However, patients with poor performance status (PS), signifi-
cant weight loss or significant hepatic or pulmonary metastases do
not often benefit from aggressive combination chemotherapy regi-
mens. Renal impairment quite often coexists in this setting and is a
further complicating factor limiting the use and effectiveness of
many chemotherapeutic agents.
Paclitaxel has already demonstrated quite significant single-
agent activity in ovarian and breast cancer (McGuire et al, 1989;
Seidman, 1995), while, at the same time, having a favourable toxi-
city profile. In vitro studies (Rangel et al, 1994; DeHaven et al,
1995), as well as early results from a phase II study in previously
untreated patients with advanced bladder cancer (Roth et al, 1994),
suggest quite significant activity in this disease. Data from a study
in which paclitaxel was used either as salvage therapy or in
patients with renal impairment (Dreicer et al, 1996) were encour-
aging, although the number ofpatients was very small.
We therefore decided to assess the response and toxicity to
single-agent paclitaxel in patients with previously treated, locally
advanced/metastatic TCC ofthe bladder or ureter.
Staging and follow-up
Before treatment, all patients had full history and complete phys-
ical examination, full blood count (FBC), urea and electrolyte esti-
mation (U and Es), liver function tests (LFTs), electrocardiogram,
chest radiography and computerized tomography scan of the
abdomen and pelvis or ultrasound, as well as bone scan if symp-
toms warranted this.
Response to treatment was assessed every two cycles, unless
there was evidence of disease progression in the meantime. The
standard WHO criteria were used for evaluation of toxicity and
response. The presence or absence of localized pain and haema-
turia were specifically noted.
Treatment
Paclitaxel (200 mg m-2 was dissolved in 11 of0.9% normal saline
and was administered intravenously over 3 h. All patients received
dexamethasone 20 mg p.o. (12 and 6 h before paclitaxel adminis-
tration), chlorpheniramine 10 mg i.v. and cimetidine 300 mg i.v.
30 min before treatment. Treatment was repeated every 3 weeks.
Table 1 Clinical characteristics
PATIENTS AND METHODS
Patient characteristics
In a three-centre open phase II study, 14 patients with advanced
bladder or ureteric TCC with measurable or evaluable disease
received single-agent paclitaxel. Their clinical characteristics are
shown in Table 1.
Prior treatment regimens and responses for these patients are
shown in Table 2. All patients received one treatment regimen
before paclitaxel.
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Age range (years) (median)
M:F
Performance score (ECOG)
0
1
2
Histology
Transitional cell carcinoma
Mixed squamous/transitional cell carcinoma
Serum creatinine range (,umol 1-') (median)
Locally advanced disease
Metastatic disease
40-73 (68)
9:5
3
7
4
13
1
70-330 (95)
4
11 (Four lung/liver,
two lung, two liver,
one peritoneal, one
bone, one bone/lymph
nodes)
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Table 2 Treatment received prior to paclitaxel
Treatment
Response Cisplatin-based chemotherapy Alkylating agent-based chemotherapy Radiotherapy
CR - - a
PR 3 1
PD 5 1 -
Adjuvant 1 1 1
treatment
Total 9 2 3
aThis patient received a combination of cisplatin-based chemotherapy and radiotherapy. CR, complete response; PR, partial response;
PD, progressive disease.
The dose, infusion rate and schedule of paclitaxel was chosen on
the basis of previous phase II and III trials in ovary, breast and
lung cancer patients, (Murphy et al, 1993; Eisenhauer et al, 1994;
Seidman, 1995).
The study was approved by the ethics committees of the three
hospitals that took part. All patients gave written informed consent.
RESULTS
Toxicity
Severe (grade 3/4) haematological toxicity was seen in 23 out of
42 courses, and two patients developed neutropenic sepsis
requiring admission to hospital and administration of intravenous
antibiotics. The first patient also developed grade 3/4 mucositis.
The other patient developed grade 3 peripheral neuropathy.
No other grade 3/4 non-haematological toxicity was noted apart
from alopecia which was universal. Toxicity was not related to
renal impairment.
Response
The median follow-up was 54 days (range 1-240). A partial remis-
sion of7.4 months was achieved in 1 ofthe 14 patients (7%) (95%
CI 2-12%). This patient had lymph node and bone metastases
which had previously responded to a combination of cisplatin,
vincristine and methotrexate. Stable disease in patients previously
progressing was seen in a further three (21%) patients. The three
patients with disease stabilization noticed reliefofpain/haematuria
for 54-164 days (range). Two patients died within 7 days oftreat-
ment and were therefore not assessable for response. The first
patient died in hospital from complications related to lung metas-
tases. The second patient deteriorated rapidly while at home and
died of unknown cause but is presumed to have had a treatment-
related death.
DISCUSSION
Treatment ofadvanced/metastatic TCC in this group ofelderly and
often frail patients poses a particularly difficult clinical problem.
Single-agent paclitaxel has the distinct advantage of not being
dependent upon renal excretion for its elimination (Keung et al,
1993; Schilder et al, 1994) when used in a group of patients who
frequently have low creatinine clearance. The patients with
moderate renal impairment in the study, as well as two previously
untreated patients with severe renal impairment (serum creatinine
> 400 umol 1-' treated off study (data not shown), did not have
enhanced toxicity when treated with paclitaxel.
Paclitaxel was of low efficacy in these relapsed patients, with
only one patient responding (7%, 95% CI 2-12%). This was in a
poor prognosis group of patients who were pretreated with one
chemotherapy regimen in addition to radiation therapy in three
cases. Some of them had poor PS, as well as multiple metastatic
sites (Table 1). The patient who responded and those who had
disease stabilization all had had cisplatin-sensitive disease in the
past, whereas those with primary chemotherapy resistance did not
respond.
Paclitaxel cannot be recommended for further investigation in
platinum-unresponsive TCC, but its activity is being further evalu-
ated in newly diagnosed patients with bladder cancer.
REFERENCES
DeHaven J, Traynelis C, Riggs DR, Fenton J and Lamm DL (1995) Taxol with or
without cisplatin reduces the growth oftransitional cell carcinoma and prostatic
carcinoma cell lines in vitro (abstract). Proc Am Assoc Cancer Res 36: A1765
Dreicer R, Gustin D, See W A and Williams R D (1996) Paclitaxel in advanced
urothelial carcinoma: its role in patients with renal insufficiency and as salvage
therapy (abstract). Proc Am Soc Clin Oncol 15: A607
Eisenhauer E, Ten-Bokkel-Huinin W and Swenerton K (1994) European-Canadian
randomized trial ofpaclitaxel in relapsed ovarian cancer: high-dose versus low-
dose and long versus short infusion. J Clin Oncol 12: 2654-2666
Keung A, Kaul S, Pinedo H, Ten Bokkel-Huinink WW and Beijnen JH (1993)
Pharmacokinetics ofTaxol given by 3-hr or 24-hr infusion to patients with
ovarian carcinoma (abstract). Proc Am Soc Clin Oncol 12: A321
McGuire W, Rowinsky E and Rosenshein NB, Grumbine FC, Ettinger DS,
Armstrong DK and Donehower RC (1989) Taxol: a unique antineoplastic agent
with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med
111: 273-279
Murphy W, Fossella F and Winn R (1993) Phase II study ofpaclitaxel in patients
with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:
384-388
Rangel C, Niell H, Miller A and Cox C (1994) Taxol and taxotere in bladder
cancer: in vitro activity and urine stability. Cantcer Chemother Pharmacol 33:
460-464
Roth BJ, Dreicer R, Einhorne LH, Neuberg D, Johnson DH, Smith JL, Hudes GR,
Schultz SM and Loehrer PJ (1994) Significant activity of Paclitaxel in
advanced transitional-cell carcinoma ofthe urothelium: a phase II trial ofthe
Eastem Cooperative Oncology Group. J Clin Onicol 12: 2264-2270
Scher H and Norton L (1992) Chemotherapy for urothelial tract malignancies:
breaking the deadlock. Semin Surg Oncol 8: 316
Schilder L, Egorin M, Zuhowski E and Rossof AH (1994) The pharmacokinetics of
taxol in a dialysis patient. Proc Am Soc Clin Oncol 13: A338
Seidman A (1995) The emerging role of paclitaxel in breast cancer therapy. Clin
Cancer Res 1: 247-256
C Cancer Research Campaign 1997 British Journal ofCancer (1997) 75(4), 606-607